*The following content is generated by AI and is for reference only.
Bivalirudin is a synthetic, direct thrombin inhibitor widely utilized in the management of patients with acute coronary syndromes undergoing percutaneous coronary intervention (PCI). Chemically, it is a 20-amino acid peptide that mimics the hirudin sequence but lacks the disulfide bridge found in natural hirudin, rendering it more stable and predictable. Its molecular formula is C97H153N25O28S2, and its CAS registry number is 136248-25-0. The molecule functions by binding reversibly to both the active site and the substrate recognition site of thrombin, effectively blocking the conversion of fibrinogen to fibrin without inducing heparin-induced thrombocytopenia (HIT), a significant advantage over traditional unfractionated heparin.
Clinically, Bivalirudin serves as a critical anticoagulant alternative for patients at high risk of bleeding or those with a history of HIT. It is frequently administered intravenously during cardiac catheterization procedures to prevent thrombotic complications associated with stent placement and balloon angioplasty. Unlike heparin, which requires monitoring via activated partial thromboplastin time (aPTT) and can lead to unpredictable dosing responses, Bivalirudin offers a shorter half-life and rapid onset of action, allowing for quicker reversal of anticoagulation if bleeding occurs. This pharmacokinetic profile makes it particularly valuable in emergency settings where precise control over coagulation status is paramount.
Furthermore, extensive clinical trials have demonstrated that Bivalirudin reduces major bleeding events compared to heparin plus glycoprotein IIb/IIIa inhibitors, although some studies suggest a potential trade-off regarding ischemic events in specific patient subgroups. Consequently, its use is often guided by individual risk assessments and institutional protocols. As a recombinant protein produced through solid-phase peptide synthesis, Bivalirudin represents a significant advancement in antithrombotic therapy, offering a safer profile for high-risk cardiovascular interventions while maintaining efficacy in preventing clot formation. Its continued relevance in modern cardiology underscores the importance of tailored anticoagulation strategies in improving patient outcomes during complex interventional procedures.